Cocrystal Pharma, Inc. (COCP): Total Liabilities
$3.38M
As of 2025-12-31
$3.60M
As of 2026-06-30
+38.5%
3-year compound annual growth
+14.2%
5-year compound annual growth
-24.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.38M | -14.0% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $3.93M | -19.3% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $4.88M | +283.0% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $1.27M | -30.9% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $1.84M | +6.1% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $1.74M | -38.5% | 2022-03-23, Balance as of period end |
| 2019-12-31 | $2.82M | +68.6% | 2021-03-17, Balance as of period end |
| 2018-12-31 | $1.67M | -89.6% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $16.03M | -29.0% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $22.56M | -60.2% | 2018-03-21, Balance as of period end |
| 2015-12-31 | $56.64M | -23.9% | 2017-03-31, Balance as of period end |
| 2014-12-31 | $74.41M | n/m | 2016-03-15, Balance as of period end |
| 2013-12-31 | $386.0K | n/a | 2015-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $3.38M | -14.0% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $7.33M | +12.4% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $3.46M | -74.7% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $10.02M | +299.0% |
| Oragenics Inc (OGEN) | 2025-12-31 | $1.79M | +6.1% |
| Indaptus Therapeutics, Inc. (INDP) | 2024-12-31 | $3.39M | +19.2% |
| Genprex, Inc. (GNPX) | 2025-12-31 | $2.20M | -12.3% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $3.94M | -18.7% |
Compare COCP, MAIA, FBLG, KALA side by side · Screen every company in Pharmaceutical Preparations ↗